Ribocure Pharmaceuticals, the first overseas R&D center of Ribo based in Sweden, announces it will move in and open a clinical trial unit at GoCo Clinic - where both patient care and research will be conducted when it’s ready in the spring of 2023.
Suzhou Ribo Life Science Co., Ltd. recently announced the Prof. Li-Ming Gan, the former Vice President and head of global clinical development for cardiovascular, renal and metabolism area at AstraZeneca CVRM R&D headquarter in Sweden, has joined Ribo and will serve as the President of Global R&D and Chief Medical Officer since 1st of Jan 2022.
Suzhou Ribo Life Science Co., Ltd. has announced the successful completion of two phase II clinical trials of ISIS 449884, an antisense oligonucleotide（ASO）drug for treatment of Type 2 Diabetes Mellitus (T2DM).
Ribo Life Science Co., Ltd. (Ribo) recently announced the completion of "A randomized, double-blind, placebo-controlled, single-dose escalating Phase I clinical study to evaluate the safety and pharmacokinetics of RBD1016 in healthy subjects" of its Class 1 siRNA drug for chronic hepatitis B in Australia.
Today Suzhou Ribo Life Science Co., Ltd. (hereinafter referred to as Ribo or the Company) signed a strategic cooperation agreement with Haihe Asymchem Fund and Asymchem, Inc. (Asymchem) for the oligonucleotide therapeutic production and construction project. The three parties will build a kilogram-level commercial-scale production base of oligonucleotide therapeutic drug substance in the Tianjin Economic-Technological Development Area.